Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02501902 |
Recruitment Status
:
Recruiting
First Posted
: July 17, 2015
Last Update Posted
: April 17, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Pancreatic Ductal Adenocarcinoma | Drug: Palbociclib Drug: Nab-Paclitaxel | Phase 1 |
The study has 2 parts:
• Part A (Dose-Escalation Cohorts): Consecutive cohorts of patients will receive escalating doses of oral palbociclib in combination with intravenous nab-P in 28-day cycles, in order to estimate the MTD(s) of the combination. The starting doses will be 75 mg palbociclib, and 100 mg/m2 nab-P. The observation period for dose-limiting toxicities (DLTs) will be from Day 1 to Day 28. Pharmacokinetic (PK) and pharmacodynamic (PD) properties of palbociclib and nab-P will also be assessed. Up to approximately 30 patients will be enrolled. The criteria for dose escalation will be based on a modified toxicity probability interval (mTPI) method.
• Part B [MTD Expansion Cohort(s)]: When the MTD(s) of palbociclib plus nab-P has been estimated with confidence, enrollment will proceed into 1 or 2 MTD expansion cohort(s) of up to 20 patients each at the MTD(s). The objective of the MTD expansion cohort(s) will be to provide additional information on safety, tolerability, biomarkers, PD activity, and PK/PD relationship for the combination regimen in order to determine the RP2D. The MTD expansion cohort(s) will only enroll patients who have not received previous treatment for their metastatic disease in order to evaluate preliminary activity of the combination in the target patient population.
All patients (in Part A and B) will receive nab-P intravenously once weekly for 3 weeks out of each 28-day cycle. Palbociclib oral dosing will be once daily on Days 1-21 of each 28-day cycle. To allow for PK evaluation of nab-P administered alone, nab-P will be administered on Day -2 for Cycle 1 only. Subsequent cycles will administer both nab-P and palbociclib on Day 1. Alternate dosing schedules for palbociclib may be explored based on emerging PK, PD, and safety data.
Patients will be treated as long as they are clinically benefiting from investigational product without unacceptable toxicity, objective disease progression, or withdrawal of consent. A modified visit schedule will be implemented for patients who are on investigational product for more than 2 years.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label Phase Ib Study Of Palbociclib (Oral Cdk 4/6 Inhibitor) Plus Abraxane (Registered) (Nab-paclitaxel) In Patients With Metastatic Pancreatic Ductal Adenocarcinoma |
Actual Study Start Date : | November 23, 2015 |
Estimated Primary Completion Date : | June 19, 2018 |
Estimated Study Completion Date : | November 20, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Palbociclib + Nab-Paclitaxel
Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
|
Drug: Palbociclib
Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
Other Name: Ibrance
Drug: Nab-Paclitaxel
Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
Other Name: Abraxane
|
- Number of participants with Dose-limiting toxicities (DLT) [ Time Frame: Baseline up to 28 days ]DLT defined as any of the following events occurring during the first 28 days of palbociclib and considered at least possibly-related to study medication: Grade 4 neutropenia lasting > 4 days; Febrile neutropenia (defined as neutropenia Grade ≥3 [ANC <1000 cells/mm3] and a body temperature ≥38.5°C) requiring antibiotic or antifungal treatment; Any Grade 4 thrombocytopenia (<25,000/mm3 or <25.0 x 109/L); Grade 3 toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea); Any palbociclib treatment delay of greater than 7 days; Omission of at least 2 of the 3 weekly doses of nab-P.
- Palbociclib Area Under the Curve (AUC) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 2, 4, 6, 8, and 24 hours post dose. Cycle 2 Days 1 and 15: Pre-dose. ]AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
- Nab-Paclitaxel Area Under the Curve (AUC) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 30 minutes, 1, 2, 4, 6, 8, 24, and 48 hours post dose. Cycle 2 Days 1 and 15: Pre-dose. ]AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
- Palbociclib Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 2, 4, 6, 8, and 24 hours post dose; Cycle 2, Days 1 and 15: Pre-dose. ]
- Nab-Paclitaxel Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 30 minutes, 1, 2, 4, 6, 8, 24, and 48 hours post dose. Cycle 2 Days 1 and 15: Pre-dose. ]
- Palbociclib Plasma Decay Half-Life (t1/2) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 2, 4, 6, 8, and 24 hours post dose; Cycle 2 Days 1 and 15: Pre-dose. ]Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
- Nab-Paclitaxel Plasma Decay Half-Life (t1/2) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 30 minutes, 1, 2, 4, 6, 8, 24, and 48 hours post dose. Cycle 2 Days 1 and 15: Pre-dose. ]Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
- Palbociclib Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 2, 4, 6, 8, and 24 hours post dose; Cycle 2 Days 1 and 15: Pre-dose. ]
- Nab-Paclitaxel Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 30 minutes, 1, 2, 4, 6, 8, 24, and 48 hours post dose. Cycle 2 Days 1 and 15: Pre-dose. ]
- Palbociclib Apparent Oral Clearance (CL/F) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 2, 4, 6, 8, and 24 hours post dose; Cycle 2 Days 1 and 15: Pre-dose. ]Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
- Nab-Paclitaxel Apparent Oral Clearance (CL/F) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 30 minutes, 1, 2, 4, 6, 8, 24, and 48 hours post dose. Cycle 2 Days 1 and 15: Pre-dose. ]Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
- Palbociclib Volume of Distribution at Steady State (Vss) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 2, 4, 6, 8, and 24 hours post dose; Cycle 2 Days 1 and 15: Pre-dose. ]Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
- Nab-Paclitaxel Volume of Distribution at Steady State (Vss) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 30 minutes, 1, 2, 4, 6, 8, 24, and 48 hours post dose. Cycle 2 Days 1 and 15: Pre-dose. ]Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
- Palbociclib Systemic Clearance (CL) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 2, 4, 6, 8, and 24 hours post dose; Cycle 2 Days 1 and 15: Pre-dose. ]CL is a quantitative measure of the rate at which a drug substance is removed from the body.
- Nab-Paclitaxel Systemic Clearance (CL) [ Time Frame: Cycle 1 Day -2 and 13: Pre-dose, 30 minutes, 1, 2, 4, 6, 8, 24, and 48 hours post dose. Cycle 2 Days 1 and 15: Pre-dose. ]CL is a quantitative measure of the rate at which a drug substance is removed from the body.
- Blood CA 19-9 Levels [ Time Frame: Day 1 of each cycle for approximately 12 months ]CA 19-9 measures the level of tumor-associated antigens found in the blood. CA 19-9 antigens are foreign substances released by pancreatic tumor cells.
- Objective Response Rate - Percentage of Participants With Complete or Partial Response [ Time Frame: Baseline until approximately 12 months. ]Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Measured from baseline until disease progression or death due to any cause.
- Duration of Response (DR) [ Time Frame: Baseline until approximately 12 months. ]Time in weeks/months from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response is calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR [which ever occurred first] that was subsequently confirmed plus 1) divided by 7 (or 30.44 if in months). DR was calculated for the subgroup of participants with a confirmed objective tumor response. DR is usually categorized by the median with its 95% Confidence Interval (CI), range and 25% and 75% percentiles.
- Progression-Free Survival (PFS) [ Time Frame: Baseline until approximately 12 months. ]The period from study entry until disease progression, death or date of last contact.
- Six-Month PFS Rate [ Time Frame: When last patient has been enrolled for 6 months. ]Percentage of patients who do not have progressive disease after 6 months on study.
- Overall Survival (OS) [ Time Frame: Baseline until approximately 13 months. ]Time in weeks or months from the start of study treatment to date of death due to any cause. OS is calculated as (the death date or last known alive date (if death date unavailable) minus the date of first dose of study medication plus 1 divided by 7 or 30.44 if in months.
- Tumor Tissue Biomarkers (p16 and Rb1 expression) [ Time Frame: Baseline and end of study treatment (approximately 9 months). ]Tumor tissue biomarkers (p16 and Rb1 expression by immunohistochemistry)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically-confirmed metastatic pancreatic ductal adenocarcinoma.
- Availability of a tumor tissue specimen. If no archived tumor tissue is available, then a de novo biopsy is required for patient participation.
- Karnofsky Performance Status 70 or greater.
- Adequate Bone Marrow, Renal, and Liver Function.
Exclusion Criteria:
- Prior treatment with a CDK 4/6 inhibitor.
- Prior treatment with nab-P for the treatment of metastatic disease.
- Patients with known CNS metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth.
- Diagnosis of any other malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
- QTc >480 msec, or family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.
- Uncontrolled electrolyte disorders.
- Cardiac or pulmonary disorders within 6 months of enrollment.
- Known human immunodeficiency virus infection.
- History of interstitial lung disease or pneumonitis.
- Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-P.
- Difficulty swallowing capsules or requirement for a feeding tube.
- Previous high-dose chemotherapy requiring stem cell rescue.
- Pregnant female patients; breastfeeding female patients; male patients with partners currently pregnant.
- Active inflammatory or other gastrointestinal disease,
- Active bleeding disorder in the past 6 months.
- Patients treated within the last 7 days prior to the start of IP with strong/moderate CYP3A4 inhibitors, strong/moderate CYP3A4 inducers, CYP2C8 inhibitors, strong/moderate CYP2C8 inducers, or drugs that are known to prolong the QT interval.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02501902
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
United States, Arizona | |
Scottsdale Healthcare Hospitals DBA HonorHealth | Recruiting |
Scottsdale, Arizona, United States, 85258 | |
Virginia G. Piper Cancer Pharmacy | Recruiting |
Scottsdale, Arizona, United States, 85258 | |
United States, California | |
UC San Diego Medical Center - La Jolla (Thornton Hospital) | Active, not recruiting |
La Jolla, California, United States, 92037-0845 | |
UC San Diego Moores Cancer Center - Investigational Drug Services | Active, not recruiting |
La Jolla, California, United States, 92037-0845 | |
UC San Diego Moores Cancer Center | Active, not recruiting |
La Jolla, California, United States, 92093 | |
UC San Diego Medical Center - Hillcrest | Active, not recruiting |
San Diego, California, United States, 92103 | |
United States, Colorado | |
Drug Shipment Address: Anschutz Cancer Pavilion | Recruiting |
Aurora, Colorado, United States, 80045 | |
University of Colorado Cancer Center | Recruiting |
Aurora, Colorado, United States, 80045 | |
University of Colorado Denver, CTO (CTRC) | Recruiting |
Aurora, Colorado, United States, 80045 | |
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) | Recruiting |
Aurora, Colorado, United States, 80045 | |
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) | Recruiting |
Aurora, Colorado, United States, 80045 | |
United States, Maryland | |
Oncology Investigational Drug Services (Drug Shipment Only) | Active, not recruiting |
Baltimore, Maryland, United States, 21231-2410 | |
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting |
Baltimore, Maryland, United States, 21231 | |
Johns Hopkins Hospital | Active, not recruiting |
Baltimore, Maryland, United States, 21287 | |
United States, Massachusetts | |
Beth Israel Deaconess Medical Center | Recruiting |
Boston, Massachusetts, United States, 02215 | |
United States, Missouri | |
Siteman Cancer Center - West County | Recruiting |
Creve Coeur, Missouri, United States, 63141 | |
Barnes-Jewish Hospital | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
Washington University Infusion Center Pharmacy | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
Washington University School of Medicine | Recruiting |
Saint Louis, Missouri, United States, 63110 | |
Siteman Cancer Center - South County | Recruiting |
Saint Louis, Missouri, United States, 63129 | |
Siteman Cancer Center | Recruiting |
Saint Peters, Missouri, United States, 63376 | |
United States, Utah | |
University of Utah, Huntsman Cancer Hospital | Recruiting |
Salt Lake City, Utah, United States, 84112 | |
University of Utah, Huntsman Cancer Institute | Recruiting |
Salt Lake City, Utah, United States, 84112 | |
Spain | |
Hospital Universitario de Fuenlabrada. Unidad de Farmacia (Only Drug Shipment) | Recruiting |
Fuenlabrada, Madrid, Spain, 28942 | |
Hospital Universitario Fuenlabrada | Recruiting |
Fuenlabrada, Madrid, Spain, 28942 | |
Hospital Universitari Vall D'Hebron | Recruiting |
Barcelona, Spain, 08035 | |
Hospital Universitario 12 de Octubre Servicio de Farmacia | Recruiting |
Madrid, Spain, 28041 | |
Hospital Universitario 12 de Octubre | Recruiting |
Madrid, Spain, 28041 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Additional Information:
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT02501902 History of Changes |
Other Study ID Numbers: |
A5481059 2015-001307-31 ( EudraCT Number ) |
First Posted: | July 17, 2015 Key Record Dates |
Last Update Posted: | April 17, 2018 |
Last Verified: | April 2018 |
Keywords provided by Pfizer:
Ibrance, palbociclib, Abraxane, nab-paclitaxel, pancreas, |
Additional relevant MeSH terms:
Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Paclitaxel Palbociclib Albumin-Bound Paclitaxel |
Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Protein Kinase Inhibitors Enzyme Inhibitors |